Anti-LIX1L / Limb and CNS expressed protein 1-like

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. LIX1L antibody detects Limb and CNS expressed protein 1-like, a cytoplasmic protein implicated in cytoskeletal regulation, cell differentiation, and organ development. Encoded by the LIX1L gene on chromosome 1p36.22, this protein shares homology with LIX1, a factor involved in limb patterning and neural morphogenesis. LIX1L contains predicted coiled-coil regions and a C-terminal domain believed to mediate protein-protein interactions important for actin organization and cellular polarity. Although its precise molecular function remains under study, LIX1L is thought to regulate cytoskeletal remodeling and epithelial-to-mesenchymal transitions during development and wound healing.LIX1L is expressed in several tissues, including the brain, liver, lung, and kidney, with enriched expression in mesenchymal and epithelial cell types. Studies suggest that LIX1L contributes to cell motility by influencing actin filament organization and adhesion dynamics. In hepatic tissue, it may participate in regeneration and fibrotic remodeling, while in the nervous system it supports neuronal morphogenesis. The protein is also expressed during embryogenesis, where it may cooperate with LIM-homeodomain transcription factors to guide organogenesis. Dysregulated expression of LIX1L has been associated with certain cancers, including hepatocellular carcinoma and glioma, where it correlates with invasive behavior and poor prognosis.The LIX1L antibody is useful in developmental, cancer, and cytoskeletal research. Western blot analysis reveals a 35 kilodalton band corresponding to the full-length protein, and immunofluorescence shows cytoplasmic staining that co-localizes with filamentous actin structures. In cell migration assays, modulation of LIX1L levels alters lamellipodia formation and motility, highlighting its cytoskeletal role. Researchers use the LIX1L antibody to characterize its distribution across tissues and to evaluate its potential as a biomarker of epithelial plasticity. NSJ Bioreagents provides this antibody validated for its applications, ensuring consistent performance in multiple applications.